Journal
CELL REPORTS
Volume 11, Issue 9, Pages 1367-1376Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2015.04.056
Keywords
-
Categories
Funding
- Canadian Institute for Health Research (CIHR)
- CIHR [MOP-123304, TMD-132558]
- Marta and Owen Boris Foundation
- J.P. Bickell Foundation
- Ontario Brain Institute
- Brain Canada Foundation
- Ontario Institute for Regenerative Medicine (OIRM)
Ask authors/readers for more resources
The clinical applicability of direct cell fate conversion depends on obtaining tissue from patients that is easy to harvest, store, and manipulate for reprogramming. Here, we generate induced neural progenitor cells (iNPCs) from neonatal and adult peripheral blood using single-factor OCT4 reprogramming. Unlike fibroblasts that share molecular hallmarks of neural crest, OCT4 reprogramming of blood was facilitated by SMAD+GSK-3 inhibition to overcome restrictions on neural fate conversion. Blood-derived (BD) iNPCs differentiate in vivo and respond to guided differentiation in vitro, producing glia (astrocytes and oligodendrocytes) and multiple neuronal subtypes, including dopaminergic (CNS related) and nociceptive neurons (peripheral nervous system [PNS]). Furthermore, nociceptive neurons phenocopy chemotherapy-induced neurotoxicity in a system suitable for high-throughput drug screening. Our findings provide an easily accessible approach for generating human NPCs that harbor extensive developmental potential, enabling the study of clinically relevant neural diseases directly from patient cohorts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available